EP2584919A1 - Prebiotic effect of galactofructose - Google Patents
Prebiotic effect of galactofructoseInfo
- Publication number
- EP2584919A1 EP2584919A1 EP11725943.2A EP11725943A EP2584919A1 EP 2584919 A1 EP2584919 A1 EP 2584919A1 EP 11725943 A EP11725943 A EP 11725943A EP 2584919 A1 EP2584919 A1 EP 2584919A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- galactofructose
- days
- food composition
- prebiotic effect
- daily doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 20
- 230000000694 effects Effects 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 241000124008 Mammalia Species 0.000 claims abstract description 19
- 230000000968 intestinal effect Effects 0.000 claims abstract description 13
- 241000186000 Bifidobacterium Species 0.000 claims description 13
- 239000006041 probiotic Substances 0.000 claims description 7
- 235000018291 probiotics Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- DKXNBNKWCZZMJT-QMRWEYQWSA-N (2s,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound O=C[C@@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DKXNBNKWCZZMJT-QMRWEYQWSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000002354 daily effect Effects 0.000 description 10
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 230000036642 wellbeing Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 235000008476 powdered milk Nutrition 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000003640 procarcinogenic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to the prebiotic effect of oligosaccharides on the intestinal flora of mammals.
- a prebiotic is a non-digestible food compound that can be broken down by the microorganisms of the intestinal flora. This breakdown gives rise to an effect on the intestinal flora of the mammal, beneficial to the health thereof since it leads to development of certain bacteria of the flora.
- bifidobacteria are known for having an important role, for example in the immune system of the hosts. Their selective development by virtue of prebiotic compounds
- the prebiotic effect of a non-living compound refers to the change, both in composition and in activity, of the intestinal flora of the host due to the ingestion of this compound, when this change has a beneficial effect on the well-being and/or the health of the host (see: Gibson and Roberfroid, J. Nutr, 125, 1401, 1995).
- probiotic refers, on the other hand, to a food supplement comprising living microorganisms, when these microorganisms have a beneficial effect on the host by improving the balance of its intestinal flora (see: Fuller, J. of Applied Bacteriology, 66 (5), 365-378, 1989).
- oligosaccharides The prebiotic effect of certains oligosaccharides is known. Described in FR2844453 is the prebiotic effect of non-digestible oligosaccharides comprising chain formations of identical or different monosaccharides, the degree of polymerization of which varies between 2 and 10. These oligosaccharides, via their prebiotic effect, may contribute to the prevention of type II diabetes.
- oligosaccharides in FR2844453 are intended for patients predisposed to type II diabetes. Taking oligosaccharides is similar to taking medication.
- the invention aims to improve the well-being of healthy mammals, via acting on their intestinal flora.
- the invention relates to galactofructose for its prebiotic effect on the intestinal flora of mammals, when it is incorporated into a food composition and when this is absorbed by the mammal in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.05 and 0.5 g.
- Galactofructose also called lactulose, is a disaccharide formed from the combination of two monosaccharide molecules, fructose and galactose. Its chemical formula is (4-0-p-D-Galactopyranosyl-P-D-fructofuranose). It is an isomerization product of lactose, which both have the same empirical formula
- galactofructose when it is absorbed in small amounts according to the invention in food compositions, improves the well- being of mammals.
- the invention also has the advantage of not interfering with the taste and the appearance (for example colour) of the food compositions.
- the galactofructose according to the invention is incorporated into a food composition.
- the expression "food composition” is understood to mean a composition intended for feeding mammals.
- the mammals are preferably human beings, although the invention can also be used for improving the well-being of various mammalian animals, such as domestic animals.
- the food composition is advantageously a composition absorbed regularly, preferably at least once a week, more preferably several times a week, and particularly preferably daily.
- Food compositions for human beings comprising at least one foodstuff such as bread, butter, milk, fermented dairy products, cereals, biscuits, beverages and fruit juices are advantageous.
- the food compositions are intended for feeding children.
- a food composition comprising powdered milk intended for infant feed is one example of a food composition for which the invention is particularly suitable.
- the galactofructose is absorbed in daily amounts, averaged over 30 days, of between 0.05 and 0.5 gram. This means that the daily doses may vary but that the total dose absorbed over one month divided by 30 is between 0.05 and 0.5 g.
- the amounts are averaged over 7 days, which means that the total dose absorbed over seven days divided by 7 is between 0.05 and 0.5 g.
- the daily doses of galactofructose, averaged over 30 days are between 0.1 and 0.5 g, more advantageously between 0.2 and 0.5 and more advantageously still between 0.2 and 0.4 g. It is recommended that the daily dose absorbed, not averaged, does not exceed 5 g, preferably does not exceed 2.5 g, more preferably does not exceed
- the daily doses of galactofructose are between 0.1 and 0.5 g, over at least 7 days, preferably at least 14 days, more preferably at least 30 days.
- galactofructose is absorbed regularly every day and the doses are no longer averages, but daily estimated values.
- the prebiotic effect according to the invention is demonstrated in concrete terms by an increase in the population of bifidobacteria in the intestinal flora of the host mammal.
- This increase is at least 10%, generally at least 25%, often at least 50%.
- the population is at least doubled.
- the population of Bifidobacterium spp bifidobacteria, expressed in log 10 is increased by 0.5 at least, which corresponds to a multiplication of the population by a factor of around 3 at least.
- Bifidobacterium spp bifidobacteria protect the gut against colonization by pathogenic bacteria.
- This protection results, on the one hand, from the competition at the surface of the cells, from the competition for essential nutrients, from the production of antimicrobial agents and from the production of compounds comprising short-chain fatty acids, which decrease the pH of the faeces and inhibit the development of pathogenic bacteria.
- Bifidobacterium spp bifidobacteria are also associated with a strengthening of the immune system, especially in children, and with a preventive action against cancer, via a reduction in the activity of enzymes that convert procarcinogenic substances into carcinogenic substances (see von Wright et al., Eur J.
- the increase in the population of bifidobacteria does not require any probiotic in the food composition. It is even recommended that the composition be substantially free thereof.
- the expression “substantially free of probiotics”, is understood to mean that the food composition alone, in the absence of galactofructose, gives rise to an increase in the population of
- the invention is preferably aimed at mammals in good health, exhibiting no signs of disease. It makes it possible to improve their well-being. Under certain circumstances, it also makes it possible to protect their good health, in a preventative manner.
- the invention also relates to a food composition as is, comprising galactofructose for its prebiotic effect on the intestinal flora of mammals, when the food composition is absorbed in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.05 and 0.5 g.
- the food composition according to the invention is advantageously a regularly absorbed composition, and preferably contains a foodstuff intended for children, such as powdered milk for infant feed.
- this is also substantially free of probiotics.
- the invention also relates to a prepackaged dose of the composition as herein described, comprising from 0.1 to 0.5 gram of galactofructose. It is recommended to absorb such a dose daily.
- the invention finally relates to a process for manufacturing a composition according to the invention, according to which a galactofructose powder, having a water content of less than 5% by weight and an average particle size D50 of less than 500 ⁇ , is mixed with a foodstuff.
- the powder may be manufactured according to the process described in FR2898516.
- the process according to the invention is particularly advantageous when the foodstuff is itself in powder form, as is the case of milk powders for feeding children, for example.
- the bifidobacterium spp population of the faeces before the test, measured by the FISH (Fluorescence In Situ Hybridization) technique was around 8.5 logl O cells/g faeces on average. At the end of the test (30 days), this population increased to around 9 log 10 in the group absorbing galactofructose according to the invention. No significant variation (taking into account natural variations in measurement) was observed in the placebo group. 30 days after the end of the ingestion, the bifidobacterium population of the galactofructose group returned to a value close to 8.75 on average. Furthermore, it was verified that the total population of anaerobic bacteria varied little during and after the test, both in the galactofructose group and in the placebo group.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pediatric Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Dairy Products (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1054956A FR2961378A1 (fr) | 2010-06-22 | 2010-06-22 | Effet prebiotique d'oligosaccharides |
| PCT/EP2011/060226 WO2011161053A1 (en) | 2010-06-22 | 2011-06-20 | Prebiotic effect of galactofructose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2584919A1 true EP2584919A1 (en) | 2013-05-01 |
Family
ID=43259763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP11725943.2A Ceased EP2584919A1 (en) | 2010-06-22 | 2011-06-20 | Prebiotic effect of galactofructose |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2584919A1 (ja) |
| JP (1) | JP2013530701A (ja) |
| FR (1) | FR2961378A1 (ja) |
| WO (1) | WO2011161053A1 (ja) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB865593A (en) * | 1956-03-10 | 1961-04-19 | Tervalon Nv | Improvements in or relating to methods of producing bifidus-active food preparations |
| JP4008974B2 (ja) * | 1996-12-12 | 2007-11-14 | 森永乳業株式会社 | ビフィズス菌増殖促進組成物及びその用途 |
| FR2844453B1 (fr) | 2002-09-13 | 2006-05-19 | Agronomique Inst Nat Rech | Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii |
| US20040191295A1 (en) * | 2003-03-28 | 2004-09-30 | Locniskar Mary Frances | Composition and method for viral inhibition |
| FR2898516B1 (fr) | 2006-03-17 | 2008-05-30 | Innov Ia Sa | Procede de preparation d'une composition pulverulente et produit tel qu'obtenu |
| EP2012807A4 (en) * | 2006-04-10 | 2009-07-08 | Dikovskiy Aleksander Vladimiro | PHARMACEUTICAL COMPOSITION FROM AN ENTEROSORBEN AND PREBIOTIKA, DOSAGE FORMS AND METHOD FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISEASES |
| ITMI20071214A1 (it) * | 2007-06-15 | 2008-12-16 | S I I T Srl Servizio Internazi | Composizioni a base di componenti prebiotici ed immunogenici per la prevenzione e il trattamento di disturbi gastroenterici da disbiosi e/o alterazioni della normale flora intestinale |
-
2010
- 2010-06-22 FR FR1054956A patent/FR2961378A1/fr active Pending
-
2011
- 2011-06-20 EP EP11725943.2A patent/EP2584919A1/en not_active Ceased
- 2011-06-20 WO PCT/EP2011/060226 patent/WO2011161053A1/en active Application Filing
- 2011-06-20 JP JP2013515837A patent/JP2013530701A/ja not_active Withdrawn
Non-Patent Citations (4)
| Title |
|---|
| ANONYMOUS: "Baby Feeding Guide | Nestlé Baby", 19 September 2014 (2014-09-19), XP055189409, Retrieved from the Internet <URL:http://web.archive.org/web/20140919195438/http://www.nestle-baby.ca/en/baby-nutrition/feeding-your-baby/baby-feeding-guide> [retrieved on 20150515] * |
| ANONYMUS: "BABY FEEDING GUIDE - FROM BIRTH TO PRE-SCHOOL!", 19 September 2014 (2014-09-19), XP055189406, Retrieved from the Internet <URL:http://www.nestle-baby.ca/sites/default/files/files/3_2_3a - Nestlebaby-Feeding-Guide(1).pdf> [retrieved on 20150515] * |
| R. NAGENDRA ET AL: "Effect of feeding milk formula containing lactulose to infants on faecal bifidobacterial flora", NUTRITION RESEARCH, vol. 15, no. 1, 1 January 1995 (1995-01-01), pages 15 - 24, XP055189305, ISSN: 0271-5317, DOI: 10.1016/0271-5317(95)91649-W * |
| See also references of WO2011161053A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2961378A1 (fr) | 2011-12-23 |
| JP2013530701A (ja) | 2013-08-01 |
| WO2011161053A1 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | Emerging prospects of macro-and microalgae as prebiotic | |
| EP1481682B1 (en) | Preparation that contains oligosaccharides and probiotics | |
| Macfarlane | Prebiotics in the gastrointestinal tract | |
| Rehman et al. | Influence of fermentable carbohydrates on the intestinal bacteria and enteropathogens in broilers | |
| Nakamura et al. | Evaluation of the effects of dietary organic germanium, ge-132, and raffinose supplementation on caecal flora in rats | |
| JP5916288B2 (ja) | 自然免疫促進作用が増強された自然免疫活性化剤の製造方法及びその製造方法で製造されたローヤルゼリー由来の自然免疫活性化剤 | |
| Haddadin et al. | The effect of royal jelly on growth and short-chain fatty acid production of probiotic bacteria and activity of bacterial procarcinogenic enzymes in rat faeces | |
| JP2823640B2 (ja) | 腸内フローラ改善物質 | |
| KR101472190B1 (ko) | 식물성 유산균 락토바실러스 플란타룸 피엠오08 사균체를 유효성분으로 포함하는 변비 예방, 치료 또는 개선용 조성물 | |
| Nguyen et al. | Synthesis of oligosaccharide-containing orange juice using glucansucrase | |
| Kil et al. | Effects of kimchi on stomach and colon health of Helicobacter pylori-infected volunteers | |
| JPWO2016136624A1 (ja) | 免疫調節剤及びその用途 | |
| EP2584919A1 (en) | Prebiotic effect of galactofructose | |
| Nakov et al. | Prebiotic effects of inulin and acacia gum | |
| Sharma et al. | Pre-and probiotics: Using functional foods in the fight against microbial resistance to antibiotics | |
| JP2006193489A (ja) | 体脂肪蓄積抑制剤 | |
| IT202000015268A1 (it) | Idrolizzato di fibra vegetale e suoi usi nell’alimentazione umana ed animale | |
| US20130316049A1 (en) | Galactofructose for its regulating effect on intestinal transit | |
| JP2006265142A (ja) | 体脂肪の蓄積抑制または低減剤 | |
| TWI786105B (zh) | 生體內酚化合物減低劑 | |
| KR20190141349A (ko) | 흑효모 발효 다당체를 유효성분으로 포함하는 장내 균총 개선 및 비만 예방, 치료용 조성물 | |
| WO2023277041A1 (ja) | 乳酸菌およびビフィズス菌増殖促進剤 | |
| Crittenden et al. | Modifying the human intestinal microbiota with prebiotics | |
| KR102133218B1 (ko) | 체지방 감소 보조제 및 베타글루칸을 유효성분으로 하는 비만 예방 또는 치료용 조성물 | |
| WO2024024906A1 (ja) | ビフィドバクテリウム・ブレーベのオリゴ糖資化促進用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20130122 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GROUPE SOLACTIS |
|
| 17Q | First examination report despatched |
Effective date: 20150522 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20170519 |